Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from CANbridge Pharmaceuticals Inc. ( (HK:1228) ).
CANbridge Pharmaceuticals Inc. announced the resignation of Dr. Fangxin Li as a non-executive director and member of the remuneration committee, effective June 25, 2025, due to changes in his work arrangements. This resignation has resulted in the remuneration committee falling below its required number of members, prompting the company to seek a suitable replacement. Additionally, the company has withdrawn an ordinary resolution related to Dr. Li’s proposed re-election at the upcoming annual general meeting, while all other meeting details remain unchanged.
More about CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for rare diseases and targeted cancers. The company operates primarily in the healthcare industry, aiming to address unmet medical needs in its market focus areas.
Average Trading Volume: 5,188,094
Technical Sentiment Signal: Hold
Current Market Cap: HK$142.3M
For detailed information about 1228 stock, go to TipRanks’ Stock Analysis page.